【安渡新闻】安渡生物开发模型引导技术平台促进抗体治疗药物开发

日前，安渡生物宣布将开发一项技术平台，用于促进抗体治疗领域在模型引导下的药物开发。该平台可突出基于抗体治疗药在药物开发阶段的药代动力学特征，从而为该阶段的决策制定提供有利参考。

Amador Bioscience announced the development of a technology platform to enhance model-informed drug development for antibody-based therapeutics. This platform characterizes the pharmacokinetics of antibody-based therapeutics and facilitates the decision-making process in drug development. 

该平台的开发工作将与香港中文大学（CUHK）医学院教授Xiaoyu Yan博士合作进行。此项目也获得了由香港特别行政区创新与科技基金（ITF）合作研究计划提供的200万港币的资金支持。

This platform development will be carried out in cooperation with Prof. Xiaoyu Yan at the School of Pharmacy, The Chinese University of Hong Kong (CUHK), with approved support of 2 million HKD through the Partnership Research Programme of Innovation and Technology Fund (ITF), Hong Kong SAR, China.

安渡生物是一家具备生物药开发及相关服务的全方位CRO，致力于提供出色的解决方案和完美的客户体验。安渡生物提供的实验室、临床研究、战略咨询及监管申报服务均符合国际标准（GLP/GCLP）和政府法规。从最初分析到最终交付物，安渡旨在通过建模和数据描述强调关键发现，以协助客户取得创新或改进生物制剂的FDA许可。

Amador Bioscience is committed to providing exceptional quality solutions and a flawless customer experience as a full-service CRO for biotherapeutics development and related services. Our laboratory, clinical research, strategic consulting, and regulatory reporting services comply with international standards (GLP/GCLP) and government regulations. From initial analysis to the final product, our objective is to assist our customers with FDA approval of novel or improved biotherapeutics by modeling and portraying the data to highlight the key findings.

香港中文大学（CUHK）是一所具有前瞻性的研究型综合大学。其中香港中文大学医学院在中国为医学实践现代化，以及药物开发及生产革新方面开展了广泛的研究活动。在2021年的QS世界大学排行榜中，香港中文大学在亚洲排名第13位，世界排名第43位。

The Chinese University of Hong Kong (CUHK) is a forward-looking comprehensive research university. The School of Pharmacy at CUHK, undertakes a wide range of research programs in modernizing pharmacy practice and revolutionizing drug development and manufacture in China. CUHK was ranked as 13th in Asia and 43rd in the world in 2021 QS World University ranking.

创新与科技基金（ITF）由创新科技署管理，旨在提升本地经济活动的增值力、生产力及竞争力。香港特区政府希望透过基金，鼓励和协助香港的企业提升科技水平，并为其业务注入更多的创新意念。合作研究计划（PRP）于2019年启动，旨在支持由研发中心、本地大学及其他指定的本地公共研究机构与当地企业合作的研究与开发项目。

Innovation and Technology Fund (ITF) 

Administered by the Innovation and Technology Commission, The Innovation and Technology Fund (ITF) aims to increase the added value, productivity and competitiveness of our economic activities. The Hong Kong SAR, China government hopes that, through the ITF, Hong Kong companies could be encouraged and assisted to upgrade their technological level and introduce innovative ideas to their businesses. Launched in January 2019, Partnership Research Programme (PRP) aims to support research and development projects undertaken by R&D Centres, local universities and other designated local public research institutes in collaboration with local companies.